Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis Inc (PSNL) drives innovation in genome-guided medicine through advanced sequencing solutions and cancer immunotherapy research. This news hub provides investors and researchers with essential updates on the company’s scientific advancements and strategic developments.
Access authoritative reporting on PSNL’s financial results, clinical trial milestones, and technology partnerships. Our curated collection includes press releases on pharmacogenomics breakthroughs, regulatory filings, and collaborative research initiatives shaping personalized medicine.
Key coverage areas include precision oncology developments, genomic data platform enhancements, and biopharma collaborations. Stay informed about innovations in neoantigen discovery and therapeutic vaccine development through verified primary sources.
Bookmark this page for real-time updates on Personalis’ contributions to next-generation diagnostics and therapeutic solutions. Monitor critical updates through our organized repository of corporate communications and third-party analysis.
Personalis, Inc. (Nasdaq: PSNL) will announce its Q2 2021 financial results on August 4, 2021, after market close. A conference call is scheduled for the same day at 2:00 PM PT / 5:00 PM ET to discuss the results and recent developments. Interested parties can join the live call via phone or access the webcast through the company's investor relations website. Personalis is recognized for its advancements in cancer genomics and population sequencing, operating a significant global sequencing operation while serving the VA MVP.
Personalis, Inc. (Nasdaq: PSNL) announced the NeXT Level Biomarkers Symposium, showcasing innovative research in cancer genomics, particularly through their NeXT Platform. The event will feature presentations on HLA loss of heterozygosity, neoantigen prediction, and the Neoantigen Presentation Score (NEOPS). Additionally, a case study from the Parker Institute for Cancer Immunotherapy will be highlighted. Richard Chen, CSO, expressed excitement about sharing advancements aimed at precision oncology. Further details and registration are available on their official website.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will participate in the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. This event will showcase the company’s advancements in population sequencing and the ImmunoID NeXT Platform, which offers comprehensive molecular data on cancer and immune response. The presentation will be available for 90 days on Personalis’ website, emphasizing their role as the sole sequencing provider for the U.S. Department of Veterans Affairs Million Veterans Program.
Personalis, Inc. (Nasdaq: PSNL) will present at Biomarkers Week Online 2021, showcasing the ImmunoID NeXT Platform for cancer immunogenomics. Erin Newburn, MS, PhD, will detail its capability to analyze tumor and immune microenvironment from a single sample. A case study on 51 late-stage melanoma patients highlights the platform's effectiveness in predicting responses to checkpoint blockade. Personalis is a co-sponsor of the event and aims to discuss its innovations in cancer genomics.
Personalis, Inc. (Nasdaq: PSNL) reported a record revenue of $20.9 million for Q1 2021, marking a 9% increase from $19.2 million in Q1 2020. Revenue from biopharma and other customers surged 74% to $7.7 million. The company added $162 million from a public offering, ending the quarter with $353.4 million in cash and equivalents. Despite these gains, net loss rose to $12.4 million, consistent with a net loss per share of $0.29. Outlook for Q2 2021 anticipates revenues of approximately $21.3 million and a net loss of $16 million to $17 million.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, will present at the 2021 Bank of America Healthcare Conference on May 13, 2021, at 5:00 p.m. Eastern Time. Renowned for its population sequencing and cancer genomics innovations, Personalis operates one of the largest sequencing programs globally, serving the U.S. Department of Veterans Affairs Million Veterans Program. Their ImmunoID NeXT Platform provides comprehensive molecular data on cancer and immune responses, enhancing next-generation therapy development.
Personalis, Inc. (Nasdaq: PSNL) will announce its Q1 2021 financial results on May 5, 2021, after market close. The company will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results and provide recent highlights. Interested participants can join the live call via phone or through the company's website. Personalis specializes in advanced genomics for cancer, serving as a key sequencing provider for major initiatives like the U.S. Department of Veterans Affairs Million Veterans Program.
Personalis, Inc. (Nasdaq: PSNL) announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2021, scheduled for April 10-15 and May 17-21, 2021.
The company will present new scientific data related to its ImmunoID NeXT platform, which enables comprehensive analysis of tumors and their immune microenvironments. Key presentations will cover topics such as HLA loss of heterozygosity, therapeutic resistance mechanisms in head and neck cancer, and antigen processing.
Personalis, Inc. (Nasdaq: PSNL) announced a collaboration with MapKure, LLC to use the Personalis NeXT Platform™ in clinical trials for BGB-3245, a next-generation B-RAF inhibitor targeting advanced solid tumors. This partnership aims to utilize the NeXT Platform for broad tumor immunogenomic profiling, facilitating the understanding of relevant biomarkers for BGB-3245. The collaboration emphasizes advanced biomarker development for improved cancer treatment. Financial details were not disclosed.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
